1. Home
  2. CAPR vs VMD Comparison

CAPR vs VMD Comparison

Compare CAPR & VMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • VMD
  • Stock Information
  • Founded
  • CAPR 2005
  • VMD 2006
  • Country
  • CAPR United States
  • VMD United States
  • Employees
  • CAPR N/A
  • VMD N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • VMD
  • Sector
  • CAPR Health Care
  • VMD
  • Exchange
  • CAPR Nasdaq
  • VMD Nasdaq
  • Market Cap
  • CAPR 322.7M
  • VMD 288.6M
  • IPO Year
  • CAPR N/A
  • VMD N/A
  • Fundamental
  • Price
  • CAPR $7.10
  • VMD $7.31
  • Analyst Decision
  • CAPR Strong Buy
  • VMD
  • Analyst Count
  • CAPR 8
  • VMD 0
  • Target Price
  • CAPR $24.75
  • VMD N/A
  • AVG Volume (30 Days)
  • CAPR 1.7M
  • VMD 331.8K
  • Earning Date
  • CAPR 08-11-2025
  • VMD 08-06-2025
  • Dividend Yield
  • CAPR N/A
  • VMD N/A
  • EPS Growth
  • CAPR N/A
  • VMD 47.14
  • EPS
  • CAPR N/A
  • VMD 0.34
  • Revenue
  • CAPR $13,392,150.00
  • VMD $240,884,000.00
  • Revenue This Year
  • CAPR $16.24
  • VMD $17.35
  • Revenue Next Year
  • CAPR $328.11
  • VMD $12.87
  • P/E Ratio
  • CAPR N/A
  • VMD $21.60
  • Revenue Growth
  • CAPR N/A
  • VMD 17.11
  • 52 Week Low
  • CAPR $3.98
  • VMD $5.93
  • 52 Week High
  • CAPR $23.40
  • VMD $9.81
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 42.24
  • VMD 63.08
  • Support Level
  • CAPR $6.90
  • VMD $6.82
  • Resistance Level
  • CAPR $8.00
  • VMD $7.51
  • Average True Range (ATR)
  • CAPR 0.55
  • VMD 0.27
  • MACD
  • CAPR -0.02
  • VMD 0.04
  • Stochastic Oscillator
  • CAPR 7.91
  • VMD 86.41

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.

Share on Social Networks: